Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience

Abstract Background Describe the efficacy of a galenic glycopyrrolate formulation and its impact on patients with sialorrhea Quality of Life (QoL), including costs analysis. Methods We performed a retrospective observational study on 21 patients who received a custom-formulated galenic glycopyrrolat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davide Zanon, Cristina Tumminelli, Anna Maria Chiara Galimberti, Lucio Torelli, Alessandra Maestro, Egidio Barbi, Natalia Maximova
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Drooling Sialorrhea Galenic Compounded drug Glycopyrrolate Pediatrics RJ1-570
Acceso en línea:	https://doaj.org/article/9280c3694ec84275ba55267413933f28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9280c3694ec84275ba55267413933f28
record_format	dspace
spelling	oai:doaj.org-article:9280c3694ec84275ba55267413933f282021-11-08T11:17:49ZCompounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience10.1186/s13052-021-01173-71824-7288https://doaj.org/article/9280c3694ec84275ba55267413933f282021-11-01T00:00:00Zhttps://doi.org/10.1186/s13052-021-01173-7https://doaj.org/toc/1824-7288Abstract Background Describe the efficacy of a galenic glycopyrrolate formulation and its impact on patients with sialorrhea Quality of Life (QoL), including costs analysis. Methods We performed a retrospective observational study on 21 patients who received a custom-formulated galenic glycopyrrolate syrup for sialorrhea for an average period of 14.3 months. We analyzed the telephone interviews with elaborated and validated questionnaires and the therapy costs comparing the brand marketed drug with the galenic formulation. Results Overall, 16 out of 21 patients (76.2%) reported a significant improvement in sialorrhea and QoL. In 14 subjects (66.7%), there was a remarkable decrease in the drooling severity; 10 individuals (47.6%) reported a reduction in drooling frequency. Nine patients experienced at least one adverse effect of glycopyrrolate therapy, and three of them stopped the treatment. No severe side effects were observed. The galenic drug significantly reduced costs for patients. Conclusions An oral glycopyrrolate solution easily administered to children with brain injuries is not commercially available in many European countries. This study demonstrates the efficacy of a compounded glycopyrrolate syrup on drooling severity, frequency and ensures a better QoL in patients and their caregivers.Davide ZanonCristina TumminelliAnna Maria Chiara GalimbertiLucio TorelliAlessandra MaestroEgidio BarbiNatalia MaximovaBMCarticleDroolingSialorrheaGalenicCompounded drugGlycopyrrolatePediatricsRJ1-570ENItalian Journal of Pediatrics, Vol 47, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Drooling Sialorrhea Galenic Compounded drug Glycopyrrolate Pediatrics RJ1-570
spellingShingle	Drooling Sialorrhea Galenic Compounded drug Glycopyrrolate Pediatrics RJ1-570 Davide Zanon Cristina Tumminelli Anna Maria Chiara Galimberti Lucio Torelli Alessandra Maestro Egidio Barbi Natalia Maximova Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
description	Abstract Background Describe the efficacy of a galenic glycopyrrolate formulation and its impact on patients with sialorrhea Quality of Life (QoL), including costs analysis. Methods We performed a retrospective observational study on 21 patients who received a custom-formulated galenic glycopyrrolate syrup for sialorrhea for an average period of 14.3 months. We analyzed the telephone interviews with elaborated and validated questionnaires and the therapy costs comparing the brand marketed drug with the galenic formulation. Results Overall, 16 out of 21 patients (76.2%) reported a significant improvement in sialorrhea and QoL. In 14 subjects (66.7%), there was a remarkable decrease in the drooling severity; 10 individuals (47.6%) reported a reduction in drooling frequency. Nine patients experienced at least one adverse effect of glycopyrrolate therapy, and three of them stopped the treatment. No severe side effects were observed. The galenic drug significantly reduced costs for patients. Conclusions An oral glycopyrrolate solution easily administered to children with brain injuries is not commercially available in many European countries. This study demonstrates the efficacy of a compounded glycopyrrolate syrup on drooling severity, frequency and ensures a better QoL in patients and their caregivers.
format	article
author	Davide Zanon Cristina Tumminelli Anna Maria Chiara Galimberti Lucio Torelli Alessandra Maestro Egidio Barbi Natalia Maximova
author_facet	Davide Zanon Cristina Tumminelli Anna Maria Chiara Galimberti Lucio Torelli Alessandra Maestro Egidio Barbi Natalia Maximova
author_sort	Davide Zanon
title	Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
title_short	Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
title_full	Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
title_fullStr	Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
title_full_unstemmed	Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
title_sort	compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience
publisher	BMC
publishDate	2021
url	https://doaj.org/article/9280c3694ec84275ba55267413933f28
work_keys_str_mv	AT davidezanon compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT cristinatumminelli compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT annamariachiaragalimberti compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT luciotorelli compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT alessandramaestro compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT egidiobarbi compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience AT nataliamaximova compoundedglycopyrrolateisacompellingchoicefordroolingchildrenfiveyearsoffacilityexperience
_version_	1718442262486056960

Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience

Ejemplares similares